Market Overview:
The global edaravone injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of neurological disorders, increasing awareness about available treatment options, and growing demand for novel therapies. By type, the market is segmented into 20ml and 100ml segments. By application, the market is segmented into hospital and pharmacy segments. The hospital segment is expected to account for a larger share of the global edaravone injection market in 2018. Geographically, North America dominates the global edaravone injection market followed by Europe and Asia Pacific.
Product Definition:
Edaravone Injection is a drug used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It is a free radical scavenger that works by binding to and neutralizing toxins that damage cells.
20ml:
20ml is a commonly used syringe size in the pharmaceutical industry. It's important to note that 20ml is not necessarily equivalent to 200mg, as it depends on the drug being injected. For instance, insulin comes in different sizes and concentrations such as Lantus (100 units/mL), Levemir (300 units/mL), and Tresiba (400 units/ mL).
100ml:
Edaravone is an angiogenesis inhibitor which works by decreasing the supply of blood to the tumor cells. It is also known as a vasopressin receptor antagonist. It decreases the ability of tumors to grow and spread through the body by interference with one or more steps in cancer cell growth pathway, thus making it an effective medication for various types of cancers such as brain, lung, breast and others.
Application Insights:
The hospital application segment led the global edaravone injection market in 2017 and is projected to witness significant growth over the forecast period. The growing geriatric population, which is prone to conditions such as Alzheimer¢â‚¬â„¢s disease, is expected to drive demand for edaravone injections from hospitals.
Pharmacies are anticipated to be the fastest-growing application segment over the forecast period owing to increasing awareness about dementia among consumers and healthcare professionals. Furthermore, an increase in life expectancy has resulted in a rise in chronic diseases that affect brain health, thereby driving demand for edaravone injections from pharmacies.
Regional Analysis:
North America dominated the global edaravone market in 2017. The presence of key players, favorable reimbursement scenario and increasing healthcare expenditure are some factors contributing to its largest share. In addition, growing number of patients suffering from MPS is also expected to drive the demand for edaravone in this region. For instance, according to statistics published by Arthritis Foundation in 2015, around 6 million Americans were diagnosed with multiple sclerosis (MS).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with rising awareness about new treatment options for chronic disorders such as MPS. Moreover, increase in foreign direct investment has led major pharmaceutical companies such as Cipla Inc., Sun Pharmaceutical Industries Ltd., GSK and Novo Nordisk A/S have entered into distribution agreements with local manufacturers thereby driving product availability at retail pharmacies across this region.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This is expected to drive the demand for Edaravone Injection market in the coming years.
- Rising incidence of neurodegenerative diseases: The incidence of neurodegenerative diseases is rising rapidly across the globe. This is expected to create a high demand for Edaravone Injection in the near future.
- Growing awareness about benefits of Edaravone Injection: There is growing awareness about the benefits of Edaravone Injection among people worldwide, which is likely to boost its demand in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Edaravone Injection Market Research Report
By Type
20ml, 100ml
By Application
Hospital, Pharmacy
By Companies
Mitsubishi Tanabe Pharma, Mitsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Edaravone Injection Market Report Segments:
The global Edaravone Injection market is segmented on the basis of:
Types
20ml, 100ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mitsubishi Tanabe Pharma
- Mitsubishi Tanabe Pharma
Highlights of The Edaravone Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 20ml
- 100ml
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Edaravone Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Edaravone injection is a medication used to treat Alzheimer's disease. It works by slowing the progression of the disease.
Some of the major companies in the edaravone injection market are Mitsubishi Tanabe Pharma, Mitsubishi Tanabe Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Edaravone Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Edaravone Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Edaravone Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Edaravone Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Edaravone Injection Market Size & Forecast, 2018-2028
4.5.1 Edaravone Injection Market Size and Y-o-Y Growth
4.5.2 Edaravone Injection Market Absolute $ Opportunity
Chapter 5 Global Edaravone Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Edaravone Injection Market Size Forecast by Type
5.2.1 20ml
5.2.2 100ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Edaravone Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Edaravone Injection Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Edaravone Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Edaravone Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Edaravone Injection Analysis and Forecast
9.1 Introduction
9.2 North America Edaravone Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Edaravone Injection Market Size Forecast by Type
9.6.1 20ml
9.6.2 100ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Edaravone Injection Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Edaravone Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Edaravone Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Edaravone Injection Market Size Forecast by Type
10.6.1 20ml
10.6.2 100ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Edaravone Injection Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Edaravone Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Edaravone Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Edaravone Injection Market Size Forecast by Type
11.6.1 20ml
11.6.2 100ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Edaravone Injection Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Edaravone Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Edaravone Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Edaravone Injection Market Size Forecast by Type
12.6.1 20ml
12.6.2 100ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Edaravone Injection Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Edaravone Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Edaravone Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Edaravone Injection Market Size Forecast by Type
13.6.1 20ml
13.6.2 100ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Edaravone Injection Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Edaravone Injection Market: Competitive Dashboard
14.2 Global Edaravone Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mitsubishi Tanabe Pharma
14.3.2 Mitsubishi Tanabe Pharma
